Trends in the management of gastro-oesophageal reflux disease
Open Access
- 1 March 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 74 (869) , 145-150
- https://doi.org/10.1136/pgmj.74.869.145
Abstract
Summary: Gastro-oesophageal reflux disease is common, with up to 10% of the general population experiencing heartburn on a daily basis. It is a chronic condition and follow-up studies indicate the presence of symptoms at least 20 years after initial diagnosis. In addition to lifestyle modifications, management usually involves the use of an acid suppressant from the H2-receptor antagonist or proton pump inhibitor groups or a prokinetic agent at some stage. In terms of initial symptom resolution and mucosal healing the proton pump inhibitors are consistently superior to the other available agents. However, while it is possible to keep the majority of patients in remission while taking medications, almost all patients have a recurrence of symptoms within six months of stopping medications. The introduction of laparoscopic fundoplication has produced promising initial results but the long-term benefits of this procedure remain to be established. The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease needs further evaluation.Keywords
This publication has 77 references indexed in Scilit:
- Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus ReportEuropean Journal of Gastroenterology & Hepatology, 1997
- Medical Management of Gastro-oesophageal Reflux DiseaseIrish Journal of Medical Science, 1996
- Diagnosis of Reflux DiseaseIrish Journal of Medical Science, 1996
- Basal acid output and gastric acid hypersecretion in gastroesophageal reflux diseaseDigestive Diseases and Sciences, 1994
- Safety of proton pump inhibitors‐‐an overview.Alimentary Pharmacology & Therapeutics, 1994
- Rolling review: gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1993
- Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitisDigestive Diseases and Sciences, 1988
- Symptomatic gastroesophageal reflux: Incidence and precipitating factorsDigestive Diseases and Sciences, 1976
- The adverse effect of chocolate on lower esophageal sphincter pressureDigestive Diseases and Sciences, 1975
- On the genesis of heartburnDigestive Diseases and Sciences, 1973